NorthRock Partners LLC Acquires 672 Shares of Zoetis Inc. $ZTS

NorthRock Partners LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 12.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,115 shares of the company’s stock after acquiring an additional 672 shares during the quarter. NorthRock Partners LLC’s holdings in Zoetis were worth $954,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. Nuveen LLC bought a new stake in Zoetis during the 1st quarter valued at $616,375,000. Mackenzie Financial Corp grew its position in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC grew its position in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Amundi grew its position in shares of Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd grew its position in shares of Zoetis by 475.9% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after purchasing an additional 743,926 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $143.45 on Wednesday. The company has a 50-day simple moving average of $148.98 and a two-hundred day simple moving average of $154.11. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The firm has a market cap of $63.58 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 2.28 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The company’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 34.42%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and cut their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.